An Angiogenic Study in Patients With Well/Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors Treated With Everolimus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Pancreatic cancer
- Focus Pharmacodynamics
- 20 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2018.
- 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.